There was significant reduction in ALT of −9.0 U/L (95% CI −11.6 to −6.4, p < 0.0001), hepatic steatosis SMD −1.0 (95% CI −3.5 to −1.5; p < 0.0001), NAFLD Activity score by −2.5 (95% CI −3.5 to −1.5, p < 0.001), decrease in waist circumference by −4.5 inches (95% CI −5.5 to −4.2, p < 0.001), decrease in HOMA- IR by −1.8 (95% CI −2.5 to −1.2, p < 0.001) and reduction in HbA1c by −0.2 (95% CI −0.4 to −0.1, p = 0.02). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.